Virology

ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital

Retrieved on: 
Thursday, January 20, 2022 - 8:00am
Biotechnology, Networks, Finance, Health, Professional Services, Biomarker, Nanoparticle, Research, Technology, Virology, HQ, LinkedIn, Biology, List of life sciences, Adoption, Seminal vesicles, CEO, Learning, Disease, Solution, University of Oxford, ARCH, Section 32, Drug development, Oxford Nanoimaging, Therapy, Neuroscience, Biomedical Research, Cell biology, McGill University Life Sciences Research Complex, Twist Bioscience, Twitter, Engineering, Life, Founder CEO, Pharmaceutical industry, Management, Medical imaging, Fine chemical

The round was led by ARCH Venture Partners and Casdin Capital , with participation from Section 32 , ARTIS Ventures , Vertical Venture Partners , Axon Ventures and private investors, including Paul Conley.

Key Points: 
  • The round was led by ARCH Venture Partners and Casdin Capital , with participation from Section 32 , ARTIS Ventures , Vertical Venture Partners , Axon Ventures and private investors, including Paul Conley.
  • ONIs technology democratizes cutting-edge science, enabling researchers to develop new angles to explore and understand the complexity of biological systems at super-resolution, said Keith Crandell, Co-founder and Managing Director at ARCH Venture Partners.
  • ARCH Venture Partners invests in advanced technology companies and is one of the worlds leading early-stage technology venture firms.
  • ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.

Oncotelic Presenting at BiotechGate Digital Partnering

Retrieved on: 
Wednesday, January 19, 2022 - 2:05pm
Survival, Forward-looking statement, Melanoma, Lung, Patient, Virology, Annual report, Glioma, Private Securities Litigation Reform Act, SEC, Form 10-K, RNA, COVID-19, Severe acute respiratory syndrome coronavirus 2, CA4P, Safety, Adult, Optimism, CEO, Cocaine, GLOBE, AML, Glioblastoma, Pancreatic cancer, New, Cancer, Intelligence, Oxigen Services, Therapy, Company, AI, Food, Communication, FDA, Food and Drug Administration Amendments Act of 2007, DIPG, Risk, Pharmaceutical industry, TGF

AGOURA HILLS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (Oncotelic or the Company) (OTCQB:OTLC), a leading developer of TGF- therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting the Company immunotherapy pipeline at BiotechGate Digital Partnering Feb 7 - 11, 2022.

Key Points: 
  • AGOURA HILLS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (Oncotelic or the Company) (OTCQB:OTLC), a leading developer of TGF- therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting the Company immunotherapy pipeline at BiotechGate Digital Partnering Feb 7 - 11, 2022.
  • Biotechgate Digital Partnering is a premier platform for business licensing and collaboration focusing on companies developing drugs, diagnostics and medical devices.
  • It is an ideal platform to unveil the fully integrated platform of immunotherapies at Oncotelic.
  • OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF- RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients.

Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration

Retrieved on: 
Monday, January 17, 2022 - 11:37am
Science, Research, Pharmaceutical, Health, Infectious Diseases, University, Education, Clinical Trials, Biomarker, Medicine, Patient, Research, Virology, AIT, Publication, International, Reuters, Precision medicine, COVID-19, Science, Knowledge, Immunomodulation, HIV disease progression rates, Rankings of universities in the United Kingdom, Disease, Student, NHS, Review, Industry, Allergy, Times Higher Education, Time, Diagnosis, Imperial, Immune system, College, Engineering, Stallergenes Greer, Imperial College London, Partnership, University, Pharmaceutical industry, Vaccine

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.
  • This underscores our commitment to advancing precision medicine for allergy sufferers, stated Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.
  • This research collaboration is a remarkable opportunity for a fruitful partnership between Imperial College London, a pioneer and world-leading university in the biomarker field, and Stallergenes Greer.
  • It will build on the recent advances of biomarker research to further develop precision medicine in AIT for the benefit of patients with allergic diseases, said Dr Mohamed Shamji, Head of the Immunomodulation and Tolerance Group, Imperial College London.

Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation

Retrieved on: 
Thursday, January 13, 2022 - 1:00pm
Medicine, Patient, Research, Virology, Stanford University, Technology, CMC, R, Protein, Oligonucleotide, CEO, Biology, DNA, Sirna, GMP, Molecular medicine, Therapy, Program, Gene editing, Drug development, Doctor of Philosophy, Multimedia, Chemical substance, RNA transfection, Neurology, Partnership, Skin, Pharmaceutical industry, Medical device, Chemistry

That is why "drug delivery technologies" are said to be the choke point of drug and gene therapies.

Key Points: 
  • That is why "drug delivery technologies" are said to be the choke point of drug and gene therapies.
  • The drug delivery technologies of N1 Life have demonstrated significant advantages in non-antigen-dependent tumor targeting, tumor tissue and cell penetration, and overcoming multi-drug resistance.
  • "We are very pleased to establish a new joint venture, Napoltec, with N1 Life, which will be featuring complementary in mutually pursuing gene therapy drug development.
  • It is committed to applying innovative drug delivery technologies to the development of clinical products that address unmet medical needs.

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022 - 1:26am
Clinical trial, Vaccination, LNP, Peking Union Medical College, Vaccine, R, Disease, COVID-19, Safety, Adult, Immunization, Prevention, DEC Systems Research Center, Quality control, CAS, Public health, AIM, Chinese Academy of Medical Sciences COVID-19 vaccine, Chinese Center for Disease Control and Prevention, Efficiency, Hospital, Tsinghua University, Wuhan Institute of Virology, Fudan University, Infection, Medicine, Institute, Polio, Institute of Biomedical Science, RNA transfection, Coronavirus, III, GMT, Virology

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery

Retrieved on: 
Tuesday, January 11, 2022 - 2:57pm
Biotechnology, Health, Science, Other Science, Pharmaceutical, Kinetics, Technion – Israel Institute of Technology, Virology, Biotechnology, Antibody, Probability, Harvard Medical School, Pfizer, Science, AbbVie, Knowledge, Informatics, Novartis, Immunology, Health, Neutralizing antibody, AstraZeneca, ADS, Goal, Doctor of Philosophy, Therapy, Bristol Myers Squibb, Engineering, LLC, Mouse, Canadian Aviation Regulations, Drug discovery, Teva Pharmaceuticals, Fine chemical, Research, Technology

AlivaMab Discovery Services , LLC (ADS), a leader in the discovery of superior antibody-based therapeutics, today announced Jane Seagal, PhD, has joined the company as Vice President of Antibody Discovery.

Key Points: 
  • AlivaMab Discovery Services , LLC (ADS), a leader in the discovery of superior antibody-based therapeutics, today announced Jane Seagal, PhD, has joined the company as Vice President of Antibody Discovery.
  • During her 11-year tenure, she contributed to over 150 antibody discovery campaigns, increased antibody discovery capacity by incorporating advanced automation platforms and informatics, introduced multiple technological improvements and built a molecular core team.
  • Jane adds to our teams diverse experience and further strengthens our leadership position in the science of antibody discovery for challenging targets, delivering on functional design goals, and engineering alternate modalities, said Justin Mika, Chief Executive Officer at AlivaMab Discovery Services.
  • AlivaMab Discovery Services (ADS) sets its partners antibody discovery programs on the fastest and most de-risked path through discovery and development.

GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

Retrieved on: 
Tuesday, January 11, 2022 - 2:00pm
Vaccine, Immunodeficiency, Research, Patient, Virology, State, Zika virus, Human, Fort Detrick, SEC, Form 10-Q, Regulation of tobacco by the U.S. Food and Drug Administration, Army of the United States, COVID-19, Malaria, State epidemiologist (Sweden), CMO, Knowledge, Fortis Healthcare, CEO, University of Virginia School of Medicine, Virginia School for Girls, GLOBE, Public health, Nasdaq, Infection, Form S-3, Company, Head, Form, Cancer, Food, Patent, FDA, GeoVax, University, Risk, Pharmaceutical industry, IQVIA, Hygiene, MD

Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Companys Chief Medical Officer (CMO).

Key Points: 
  • Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Companys Chief Medical Officer (CMO).
  • Dr. McKee brings over 30 years of experience in research and development, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections.
  • Dr. McKee subsequently served as State Epidemiologist in North Carolina, and as Senior Director of Clinical Research at DynPort Vaccine Company.
  • I am pleased to be joining the GeoVax team, said Dr. McKee.

TC BioPharm (Holdings) Limited Names Chris Camarra Executive Vice President, Communications

Retrieved on: 
Tuesday, January 11, 2022 - 1:30pm
Patient, Technology, Virology, Degenerative disease, IPO, Public relations, Executive, Holding, Acute myeloid leukemia, Communication, Nasdaq, TCB, Company, CAR, Conditional sentence, Cancer, TC, Canadian Aviation Regulations, Awareness, Vaccine, Management, COVID-19

EDINBURGH, Scotland, Jan. 11, 2022 /PRNewswire/ --TC BioPharm (Holdings) Limited ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, has appointed Chris Camarra to the newly created role of Executive Vice President, Communications.

Key Points: 
  • EDINBURGH, Scotland, Jan. 11, 2022 /PRNewswire/ --TC BioPharm (Holdings) Limited ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, has appointed Chris Camarra to the newly created role of Executive Vice President, Communications.
  • Mr. Camarra joins TC BioPharm as it prepares for an upcoming Nasdaq IPO later this month and begins to expand US presence and communications efforts.
  • Mr. Camarra joins TC BioPharm with nearly 20 years of experience in the communications vertical for publicly traded companies.
  • "Establishing an effective communications plan and leveraging strategic relationships within the investment community is critical for us as we prepare for our initial public offering," said Bryan Kobel, Chief Executive Officer of TC BioPharm.

ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities

Retrieved on: 
Tuesday, January 11, 2022 - 1:00pm
Forward-looking statement, Research, Patient, Spanish, CNMV, Person, Mercado, Genomics, CNS, University of Barcelona, Takeda Oncology, Public expenditure, ISIN, Molecular biology, Oncology, CEO, LSD1, GLOBE, Amgen, Department, Royal, Catalan Institute of Nanoscience and Nanotechnology (ICN2), Harvard Medical School, Nasdaq, Dana–Farber Cancer Institute, Doctor of Philosophy, Biochemistry, Sale, Hematology, Communication, Business, Mission statement, Prospectus, Hospital, Senior, University, ORY, Medicine, Pharmaceutical industry, Takeda, Virology

Dr. Limns broad scientific and clinical research experience in hematology and oncology will be key in developing Oryzons clinical programs.

Key Points: 
  • Dr. Limns broad scientific and clinical research experience in hematology and oncology will be key in developing Oryzons clinical programs.
  • She joins Oryzon from Deciphera Pharmaceuticals, a Nasdaq listed company, where she was Senior Director and Global Program Leader of several assets.
  • Prior to that, she held roles of increasing responsibility at Millenium Pharmaceuticals and Takeda, her last as the Head of the Oncology Pipeline, Global Medical Affairs at Takeda.
  • Dr. Carlos Buesa, President and CEO of Oryzon said: Dr. Limn is an outstanding professional with enormous molecular and clinical knowledge in oncology.

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

Retrieved on: 
Tuesday, January 11, 2022 - 12:45pm
People, Ophthalmology, Woman, Champaign County, Illinois, Nursing, Patient, Horizon Therapeutics, Research, Virology, BSN, Healthcare Businesswomen's Association, Health, Inflammation, R, Mentorship, COO, Science, NYSE, Growth, NASDAQ, INC, Leadership, Culture, Association, Multimedia, ABBV, University, Pharmaceutical industry, Management, Upadacitinib, AbbVie, Horizon

LOS ANGELES, Jan. 11, 2022 /PRNewswire/ --ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO).

Key Points: 
  • LOS ANGELES, Jan. 11, 2022 /PRNewswire/ --ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO).
  • "On behalf of the entire ACELYRIN leadership team, I am delighted to welcome Melanie as our chief operating officer.
  • She joins us with a strong operational background and has led a variety of R&D functions in multiple therapeutic areas," said Shao-Lee Lin, M.D., Ph.D., co-founder and chief executive officer of ACELYRIN.
  • "I am thrilled to join ACELYRIN and this team of passionate colleagues as we work together to change patients' lives with innovative drug therapies," said Ms. Gloria.